Dr. Arvind Cavale, M.D
NPI: 1457354581
Total Payments
$58,629
2024 Payments
$1,702
Companies
11
Transactions
111
Medicare Patients
3,366
Medicare Billing
$467,642
Payment Breakdown by Category
Research$55,085 (94.0%)
Travel$2,458 (4.2%)
Food & Beverage$761.08 (1.3%)
Consulting$128.50 (0.2%)
Other$125.00 (0.2%)
Gifts$59.40 (0.1%)
Education$11.71 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,085 | 27 | 94.0% |
| Travel and Lodging | $2,458 | 10 | 4.2% |
| Food and Beverage | $761.08 | 50 | 1.3% |
| Consulting Fee | $128.50 | 21 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125.00 | 1 | 0.2% |
| Gift | $59.40 | 1 | 0.1% |
| Education | $11.71 | 1 | 0.0% |
Payments by Type
Research
$55,085
27 transactions
General
$3,544
84 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic MiniMed, Inc. | $46,219 | 14 | $0 (2020) |
| Medtronic, Inc. | $6,237 | 4 | $0 (2022) |
| Eli Lilly and Company | $3,657 | 12 | $0 (2022) |
| ABBVIE INC. | $1,662 | 12 | $0 (2024) |
| KVK-Tech, Inc. | $277.78 | 57 | $0 (2022) |
| Lilly USA, LLC | $206.55 | 5 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $144.37 | 3 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $125.00 | 1 | $0 (2022) |
| MannKind Corporation | $59.40 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $23.11 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,702 | 14 | ABBVIE INC. ($1,662) |
| 2023 | $59.40 | 1 | MannKind Corporation ($59.40) |
| 2022 | $3,827 | 18 | Eli Lilly and Company ($3,657) |
| 2021 | $6,357 | 22 | Medtronic, Inc. ($6,222) |
| 2020 | $46,279 | 42 | Medtronic MiniMed, Inc. ($46,157) |
| 2019 | $140.07 | 10 | Lilly USA, LLC ($100.29) |
| 2018 | $62.81 | 2 | Medtronic MiniMed, Inc. ($62.81) |
| 2017 | $201.72 | 2 | SANOFI-AVENTIS U.S. LLC ($107.17) |
All Payment Transactions
111 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/11/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Rare Disease | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $643.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $98.79 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 09/20/2023 | MannKind Corporation | AFREZZA (Drug) | Gift | In-kind items and services | $59.40 | General |
| Category: DIABETES MEDICINE | ||||||
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $652.55 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $487.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $259.00 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $236.70 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $230.70 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $183.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $183.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $180.00 | General |
| 08/30/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $139.98 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $39.80 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CEP298 EWIS | Medtronic MiniMed, Inc. | $46,142 | 11 |
| CEP298 EWIS | Medtronic, Inc. | $6,222 | 3 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,662 | 12 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $1,059 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 996 | 2,252 | $302,660 | $129,125 |
| 2022 | 8 | 869 | 1,934 | $315,290 | $122,599 |
| 2021 | 8 | 770 | 1,878 | $304,690 | $121,547 |
| 2020 | 8 | 731 | 1,603 | $254,135 | $94,371 |
Total Patients
3,366
Total Services
7,667
Medicare Billing
$467,642
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 330 | 538 | $107,440 | $50,450 | 47.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 332 | 544 | $92,380 | $34,851 | 37.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 202 | 1,036 | $62,570 | $27,510 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 54 | 54 | $24,300 | $8,940 | 36.8% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 33 | 34 | $8,500 | $4,068 | 47.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $3,750 | $1,909 | 50.9% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 31 | 31 | $3,720 | $1,398 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 307 | 570 | $108,300 | $55,464 | 51.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 280 | 423 | $50,760 | $28,675 | 56.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 161 | 818 | $122,700 | $22,687 | 18.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 45 | 45 | $18,000 | $7,482 | 41.6% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 26 | 27 | $6,750 | $3,577 | 53.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 19 | $4,370 | $2,796 | 64.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 13 | $1,560 | $970.19 | 62.2% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2022 | 19 | 19 | $2,850 | $948.13 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 303 | 598 | $113,620 | $60,613 | 53.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 232 | 374 | $44,880 | $24,943 | 55.6% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 136 | 803 | $120,450 | $23,302 | 19.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 32 | 32 | $12,800 | $5,764 | 45.0% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 25 | 25 | $6,250 | $3,275 | 52.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 11 | 12 | $2,670 | $1,685 | 63.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 12 | 15 | $1,800 | $1,048 | 58.2% |
| 95249 | Continuous monitoring of glucose in tissue fluid using sensor under skin | Office | 2021 | 19 | 19 | $2,220 | $916.56 | 41.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 274 | 539 | $99,715 | $45,282 | 45.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 249 | 380 | $43,700 | $21,056 | 48.2% |
About Dr. Arvind Cavale, M.D
Dr. Arvind Cavale, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Feasterville Trevose, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457354581.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arvind Cavale, M.D has received a total of $58,629 in payments from pharmaceutical and medical device companies, with $1,702 received in 2024. These payments were reported across 111 transactions from 11 companies. The most common payment nature is "" ($55,085).
As a Medicare-enrolled provider, Cavale has provided services to 3,366 Medicare beneficiaries, totaling 7,667 services with total Medicare billing of $467,642. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Feasterville Trevose, PA
- Active Since 05/23/2005
- Last Updated 11/09/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1457354581
Products in Payments
- ARMOUR THYROID (Drug) $1,563
- NATPARA (PARATHYROID HORMONE) (Drug) $125.00
- SOLIQUA (Drug) $107.17
- TRULICITY (Drug) $100.29
- HUMULIN (Drug) $94.55
- Minimed 630G (Device) $62.81
- AFREZZA (Drug) $59.40
- TOUJEO (Biological) $24.60
- STRENSIQ (Biological) $23.11
- QUTENZA (Drug) $17.32
- MINIMED 770G (Device) $14.81
- LANTUS (Drug) $12.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.